Jacobs & Co. CA Has $4.09 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Jacobs & Co. CA boosted its stake in Kenvue Inc. (NYSE:KVUE) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 191,500 shares of the company’s stock after purchasing an additional 4,029 shares during the quarter. Jacobs & Co. CA’s holdings in Kenvue were worth $4,088,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fortitude Family Office LLC grew its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. First Hawaiian Bank grew its holdings in shares of Kenvue by 36.6% during the fourth quarter. First Hawaiian Bank now owns 26,095 shares of the company’s stock worth $557,000 after purchasing an additional 6,997 shares during the last quarter. Farmers Trust Co. grew its holdings in shares of Kenvue by 1.8% during the fourth quarter. Farmers Trust Co. now owns 217,218 shares of the company’s stock worth $4,638,000 after purchasing an additional 3,767 shares during the last quarter. Fulton Bank N.A. grew its holdings in shares of Kenvue by 7.3% during the fourth quarter. Fulton Bank N.A. now owns 78,423 shares of the company’s stock worth $1,674,000 after purchasing an additional 5,329 shares during the last quarter. Finally, Bard Financial Services Inc. grew its holdings in shares of Kenvue by 1.9% during the fourth quarter. Bard Financial Services Inc. now owns 108,790 shares of the company’s stock worth $2,323,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.7 %

NYSE KVUE traded down $0.36 on Friday, reaching $20.74. The company had a trading volume of 4,956,311 shares, compared to its average volume of 7,718,135. The stock has a market capitalization of $39.76 billion, a P/E ratio of 37.71, a P/E/G ratio of 2.02 and a beta of 1.46. The company’s fifty day moving average is $22.66 and its 200 day moving average is $21.56. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.31 EPS. Sell-side analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.95%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analyst Weigh In

Several analysts recently commented on KVUE shares. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Barclays raised Kenvue to a “hold” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.